Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Muggia

Showing results (351-360 of 424) with videos related to

Pageof 43
Sort By:
Cancer Treatment Reports|August 1, 1977
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agentsD D Von Hoff, M Rozencweig, W T Soper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1984
Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastineL J Laubenstein, R L Krigel, C M Odajnyk, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group studyS M Grunberg, J J Crowley, R B Livingston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 18, 2013
BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groupsT Safra, W C Lai, L Borgato, et al.
The Oncologist|November 2, 2014
Chronic thalidomide and chemoembolization for hepatocellular carcinomaJennifer Wu, Jennifer Ng, Paul J Christos, et al.
Journal of the National Cancer Institute|October 16, 1996
Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexolF M Muggia, T W Synold, E M Newman, et al.
Annals of Internal Medicine|November 1, 1979
Risk factors for doxorubicin-induced congestive heart failureD D Von Hoff, M W Layard, P Basa, et al.
The American Journal of Medicine|April 1, 1985
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breastJ L Speyer, M D Green, N Dubin, et al.
Journal of the National Cancer Institute|July 21, 1993
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesisM S Ray, F M Muggia, C G Leichman, et al.
Cancer Treatment Reports|December 1, 1984
Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot studyM Levin, K J Pandya, J D Khandekar, et al.
Pageof 43

Showing results (351-360 of 424) with videos related to

Sort By:
Pageof 43
Cancer Treatment Reports|August 1, 1977
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agentsD D Von Hoff, M Rozencweig, W T Soper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1984
Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastineL J Laubenstein, R L Krigel, C M Odajnyk, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group studyS M Grunberg, J J Crowley, R B Livingston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 18, 2013
BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groupsT Safra, W C Lai, L Borgato, et al.
The Oncologist|November 2, 2014
Chronic thalidomide and chemoembolization for hepatocellular carcinomaJennifer Wu, Jennifer Ng, Paul J Christos, et al.
Journal of the National Cancer Institute|October 16, 1996
Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexolF M Muggia, T W Synold, E M Newman, et al.
Annals of Internal Medicine|November 1, 1979
Risk factors for doxorubicin-induced congestive heart failureD D Von Hoff, M W Layard, P Basa, et al.
The American Journal of Medicine|April 1, 1985
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breastJ L Speyer, M D Green, N Dubin, et al.
Journal of the National Cancer Institute|July 21, 1993
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesisM S Ray, F M Muggia, C G Leichman, et al.
Cancer Treatment Reports|December 1, 1984
Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot studyM Levin, K J Pandya, J D Khandekar, et al.
Pageof 43